Health authorities and medical researchers are increasingly looking beyond diabetes and obesity to target sleep apnea using popular GLP-1 receptor agonist medications, a therapeutic class that includes Ozempic. According to recent regulatory and clinical developments, drugs such as Zepbound have gained specific approvals to address this breathing disorder, altering treatment landscapes.
In June, Health Canada approved the GLP-1 receptor agonist Zepbound for the treatment of sleep apnea in adults with obesity, citing clinical trial data showing notable reductions in breathing interruptions during sleep. According to regulatory documentation, clinical studies supporting the decision demonstrated that patients experienced a decrease of 25 breathing interruptions per hour.
Medical experts note that while weight loss drives the primary therapeutic response, emerging research points to secondary benefits. Dr. Marc Donath, an endocrinologist who practiced in Switzerland until last year, has prescribed GLP-1 therapies to more than a hundred Swiss patients suffering from sleep apnea. “I even have patients who have been able to get rid of their continuous positive airway pressure machine,” he states.
To understand the clinical mechanics behind these developments, researchers have mapped out how these medications function beyond traditional metabolic control. Originally used in people with diabetes because they stimulate insulin production, a hormone that facilitates the passage of sugar from the blood to the cells, GLP-1 receptor agonists mimic an intestinal hormone secreted during meals to induce a sense of satiety. As clinical trials tracked patient outcomes, weight reduction emerged as a consistent effect, prompting regulatory expansions into obesity care and now sleep-related breathing disorders.
Clinical Evidence and Respiratory Metrics
Recent scientific literature highlights quantifiable improvements in sleep architecture and respiratory stability among patients receiving GLP-1 therapies. A meta-analysis published in the journal Sleep and Breathing by Dr. Juliana Giorgi, a cardiologist at the Hôpital syro-libanais de São Paulo, Brazil, assessed data from 1,000 patients—more than two-thirds of whom were men—and evaluated molecules including Zepbound.
"GLP-1 receptor agonists clearly reduce the severity of sleep apnea," Dr. Giorgi explains.
Medical definitions classify sleep apnea by breathing interruptions per hour, where a mild condition involves 5 to 15 hourly breathing interruptions and severe involves more than 30 interruptions per hour. Epidemiological data published in the Journal of Clinical Sleep Medicine in 2024 underscores the intersection of weight and pathology, indicating that sleep apnea affects individuals at a healthy weight, overweight patients, and obese patients.
Metabolic Mechanisms and Lifestyle Integration
Researchers continue to investigate whether the reduction in sleep apnea severity stems entirely from weight loss or if concurrent biological mechanisms play a role. Dr. Giorgi points out that while the primary effect ties directly to weight reduction and concurrent decreases in blood pressure, other studies have demonstrated an independent anti-inflammatory effect. “And new agonists that are coming will have even more effects on sleep apnea, inflammation, and weight loss,” she notes.
Dr. Donath shares the assessment that weight loss explains the bulk of the therapeutic impact, while acknowledging that obesity itself increases inflammation. Regulatory frameworks emphasize that pharmacological intervention does not replace standard devices or lifestyle measures. According to Health Canada guidelines, Zepbound is reserved for patients with a body mass index (BMI) greater than 30 who suffer from sleep apnea, and must be prescribed alongside a reduced-calorie diet and physical exercise. It does not replace continuous positive airway pressure (CPAP) therapy.
“Of course, you don’t just give a GLP-1 and then say goodbye to the patient,” Dr. Donath observes. “It has to be accompanied by a change in lifestyle habits. But it is much easier to make these changes when you are taking a GLP-1.”
Reimbursement Landscapes and Broader Cardiovascular Implications
Access to these treatments varies significantly by jurisdiction, hinging on health technology assessments and public reimbursement policies. In Canada, public coverage for Zepbound’s new indication depends on evaluations by bodies such as the Institut national d’excellence en santé et en services sociaux (INESSS), which makes recommendations for the inclusion of medications among reimbursed treatments. “We’ll see how it gets reimbursed here,” Dr. Donath says, contrasting the Canadian framework with Switzerland, where he notes that GLP-1 therapies have been reimbursed for sleep apnea for several years.
Population-level adoption of GLP-1 medications reflects growing utilization rates. In the United States, polling data published by Gallup shows that 11% of people currently take a GLP-1 medication, while 15% have already taken one.
Looking ahead, clinical investigators anticipate that next-generation medications—called triple or quadruple agonists because they combine several molecules influencing appetite—will yield enhanced efficacy. Dr. Giorgi also authored a study published this year in Current Diabetes Reports demonstrating that current GLP-1 therapies are effective against the accumulation of plaque in non-coronary arteries, a condition affecting 10% of North American adults and increasing cardiovascular risk by two to six times. While a large-scale study published last December did not detect a positive effect of GLP-1s on the risk of Alzheimer’s, Dr. Giorgi maintains optimism that forthcoming combinations of agonists may be effective against dementia and other psychiatric disorders through their anti-inflammatory effect.
Health officials and regulatory agencies have not announced further scheduling updates regarding expanded approvals, leaving patients and clinicians to monitor ongoing formulary reviews and clinical trial readouts.
Worth a look